In a trial of 12 patients with Type 1 diabetes, Biodel’s two formulations showed significantly more rapid absorption rates and declines from peak concentrations. Discomfort levels associated with BIOD-250 were comparable to Humalog, though those related to BIOD-238 were significantly higher.

Read more